The latest news about addiction and substance abuse research
Children of drug abusers are at high risk for a wide-range of negative outcomes, including developmental and cognitive disabilities and substance abuse disorders.
Addiction and bipolar disorder are commonly co-occurring disorders, with up to 60% of individuals with bipolar disorder experiencing some form of substance abuse in their lifetime. While it is known that genetic factors contribute substantially to the likelihood of developing either illness, new studies suggest shared genetic roots for both disorders.
A family-based prevention program designed to help adolescents avoid substance use and other risky behavior proved especially effective for a group of young teens with a genetic risk factor contributing toward such behavior, according to a new study by researchers at the University of Georgia. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA), components of the National Institutes of Health, supported the study, which appears in the May/June issue of Child Development.
Some of the same brain mechanisms that fuel drug addiction in humans accompany the emergence of compulsive eating behaviors and the development of obesity in animals, according to research funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health.
The problematic use of mobile phones is associated with addictive personality traits, according to a study published in CyberPsychology & Behavior.
Chronic use of ketamine can lead to cognitive impairments, according to a study published in the journal Addiction.
In 2009, The American Journal of Family Therapy published research that investigated the relationship between family functioning and adolescent addiction. The research was conducted by Mimma Tafa and Roberto Baiocoo, both psychologists from the University of Rome.
Researchers have identified a key epigenetic mechanism in the brain that helps explain cocaine’s addictiveness, according to research funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.
Immunization with an experimental anti-cocaine vaccine resulted in a substantial reduction in cocaine use in 38 percent of vaccinated patients in a clinical trial supported by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. The study, published in the October issue of Archives of General Psychiatry, is the first successful, placebo-controlled demonstration of a vaccine against an illicit drug of abuse.